Elivaldogene autotemcel

艾基干赛

Report date: 2026/03/26 20:00:17

Base Information

Drug NameElivaldogene autotemcel
Drug Alias NameAdrenoleucodystrophy gene therapy - bluebird bioElivaldogene tavalentivec (bluebird bio)elivaldogene tavalentivecLenti-DSkysona
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCell replacementsABCD1 gene stimulants
TargetsATP Binding Cassette Subfamily D Member 1
Therapy Area/IndicationsAdrenoleukodystrophy
Global Approved IndicationsAdrenoleukodystrophy
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/07/27
Country/TerritoryUnited StatesAustraliaGermany +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenetix Biotherapeutics IncInserm
China Registration ClassN/A

Develop Information

Active CompaniesGenetix Biotherapeutics Inc
Inactive CompaniesBluebird Bio (Netherlands) Bv
Active IndicationsAdrenoleukodystrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A